Journal of Clinical Oncology, Vol 16, 27-34, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group

U Tirelli, D Errante, M Van Glabbeke, I Teodorovic, JC Kluin-Nelemans, J Thomas, D Bron, G Rosti, R Somers, V Zagonel and EM Noordijk
Division of Medical Oncology and AIDS, Aviano Cancer Center, Italy. oma@ets.it

PURPOSE: We report the results of a randomized study of the European Organization for Research and Treatment of Cancer (EORTC) Lymphoma Group, which compared a chemotherapy regimen specifically devised for elderly patients, ie, etoposide, mitoxantrone, and prednimustine (VMP), versus the standard regimen of cyclophosphamide, doxorobucin, vincristine, and prednisone (CHOP) in patients older than 70 years of age with intermediate- and high-grade non-Hodgkin's lymphoma (NHL). PATIENTS AND METHODS: Patients older than 70 years of age with stage II, III, or IV intermediate- and high-grade NHL, with an Eastern Cooperative Oncology Group (ECOG) performance status less than 4 and acceptable cardiac, renal, and liver function were randomized to receive six courses of VMP or six courses of CHOP. Between February 1989 and June 1994, 130 patients aged 70 to 93 years (median, 75) were enrolled and 120 were assessable for response, 60 patients in each arm. RESULTS: Overall objective response rates were 50% and 77% in VMP- and CHOP-treated patients, respectively (P = .01), while complete response (CR) rates were borderline significant (27% v 45%; P = .06). At 2 years, the progression-free survival (PFS) rate was 25% with VMP versus 55% with CHOP (P = .002) and the overall survival (OS) rate was 30% with VMP versus 65% with CHOP (P = .004). Statistically significant more alopecia and neurologic and gastrointestinal toxicities were reported with CHOP. CONCLUSION: CHOP is the standard regimen for patients > or = 70 years of age with stage II to IV intermediate- and high-grade NHL.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. Extermann and H. B. Muss Conducting Clinical Trials for Patients Who Are Frail or Elderly ASCO Educational Book, January 1, 2009; 2009(1): 289 - 293. [Abstract] [Full Text] [PDF]

				C. Thieblemont and B. Coiffier Lymphoma in Older Patients J. Clin. Oncol., May 10, 2007; 25(14): 1916 - 1923. [Abstract] [Full Text] [PDF]

				T. J. Smith, J. Khatcheressian, G. H. Lyman, H. Ozer, J. O. Armitage, L. Balducci, C. L. Bennett, S. B. Cantor, J. Crawford, S. J. Cross, et al. 2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline J. Clin. Oncol., July 1, 2006; 24(19): 3187 - 3205. [Abstract] [Full Text] [PDF]

				S. Monfardini, S. M. L. Aversa, V. Zoli, L. Salvagno, A. Bianco, R. Bordonaro, G. Benevolo, M. Crugnola, G. Crivellari, P. Vivaldi, et al. Vinorelbine and prednisone in frail elderly patients with intermediate-high grade non-Hodgkin's lymphomas Ann. Onc., August 1, 2005; 16(8): 1352 - 1358. [Abstract] [Full Text] [PDF]

				J. K. Doorduijn and P. Sonneveld In Reply: J. Clin. Oncol., July 20, 2005; 23(21): 4799 - 4799. [Full Text] [PDF]

				L. Harper and C. O. Savage ANCA-associated renal vasculitis at the end of the twentieth century--a disease of older patients Rheumatology, April 1, 2005; 44(4): 495 - 501. [Abstract] [Full Text] [PDF]

				R. T. Penson, K. J. Daniels, and T. J. Lynch Jr. Too Old to Care? Oncologist, June 1, 2004; 9(3): 343 - 352. [Abstract] [Full Text] [PDF]

				J.K. Doorduijn, B. van der Holt, G.W. van Imhoff, K.G. van der Hem, M.H.H. Kramer, M.H.J. van Oers, G.J. Ossenkoppele, M.R. Schaafsma, L.F. Verdonck, G.E.G. Verhoef, et al. CHOP Compared With CHOP Plus Granulocyte Colony-Stimulating Factor in Elderly Patients With Aggressive Non-Hodgkin's Lymphoma J. Clin. Oncol., August 15, 2003; 21(16): 3041 - 3050. [Abstract] [Full Text] [PDF]

				D. M. Fink-Bennett and K. Thomas 90Y-Ibritumomab Tiuxetan in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma J. Nucl. Med. Technol., June 1, 2003; 31(2): 61 - 68. [Abstract] [Full Text] [PDF]

				E. M. Bessell, A. Burton, A. P. Haynes, J. Glaholm, J. A. Child, M. H. Cullen, J. M. Davies, G. M. Smith, I. O. Ellis, A. Jack, et al. A randomised multicentre trial of modified CHOP versus MCOP in patients aged 65 years and over with aggressive non-Hodgkin's lymphoma Ann. Onc., February 1, 2003; 14(2): 258 - 267. [Abstract] [Full Text] [PDF]

				S. Limat, K. Demesmay, L. Voillat, Y. Bernard, E. Deconinck, A. Brion, A. Sabbah, M. C. Woronoff-Lemsi, and J. Y. Cahn Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin's lymphoma Ann. Onc., February 1, 2003; 14(2): 277 - 281. [Abstract] [Full Text] [PDF]

				P. L. Zinzani, F. Gherlinzoni, S. Storti, A. Zaccaria, E. Pavone, L. Moretti, P. Gentilini, L. Guardigni, A. De Renzo, P. P. Fattori, et al. Randomized trial of 8-week versus 12-week VNCOP-B plus G-CSF regimens as front-line treatment in elderly aggressive non-Hodgkin's lymphoma patients Ann. Onc., September 1, 2002; 13(9): 1364 - 1369. [Abstract] [Full Text] [PDF]

				B. Coiffier, E. Lepage, J. Briere, R. Herbrecht, H. Tilly, R. Bouabdallah, P. Morel, E. Van Den Neste, G. Salles, P. Gaulard, et al. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma N. Engl. J. Med., January 24, 2002; 346(4): 235 - 242. [Abstract] [Full Text] [PDF]

				C. T. Kouroukis, G. P. Browman, R. Esmail, and R. M. Meyer Chemotherapy for Older Patients with Newly Diagnosed, Advanced-Stage, Aggressive-Histology Non-Hodgkin Lymphoma: A Systematic Review Ann Intern Med, January 15, 2002; 136(2): 144 - 152. [Abstract] [Full Text] [PDF]

				L. Balducci, G. H. Lyman, and H. Ozer Patients Aged {>=} 70 Are at High Risk for Neutropenic Infection and Should Receive Hemopoietic Growth Factors When Treated With Moderately Toxic Chemotherapy J. Clin. Oncol., March 1, 2001; 19(5): 1583 - 1585. [Full Text] [PDF]

				D. Caselli, C. Klersy, M. de Martino, C. Gabiano, L. Galli, P. A. Tovo, and M. Arico Human Immunodeficiency Virus-Related Cancer in Children: Incidence and Treatment Outcome--Report of the Italian Register J. Clin. Oncol., November 15, 2000; 18(22): 3854 - 3861. [Abstract] [Full Text] [PDF]

				L. Balducci and M. Extermann Management of Cancer in the Older Person: A Practical Approach Oncologist, June 1, 2000; 5(3): 224 - 237. [Abstract] [Full Text]

				A. Moreno, G. Colon-Otero, and L. A. Solberg Jr. The Prednisone Dosage in the CHOP Chemotherapy Regimen for Non-Hodgkin's Lymphomas (NHL): Is There a Standard? Oncologist, June 1, 2000; 5(3): 238 - 249. [Abstract] [Full Text]

				P. L. Zinzani, S. Storti, A. Zaccaria, L. Moretti, M. Magagnoli, E. Pavone, P. Gentilini, L. Guardigni, M. Gobbi, P. P. Fattori, et al. Elderly Aggressive-Histology Non-Hodgkin's Lymphoma: First-Line VNCOP-B Regimen Experience on 350 Patients Blood, July 1, 1999; 94(1): 33 - 38. [Abstract] [Full Text] [PDF]

				P. G. Gobbi, C. Pieresca, M. L. Ghirardelli, N. DiRenzo, M. Federico, F. Merli, E. Iannitto, V. Pitini, G. Grignani, A. Donelli, et al. Long-Term Results From MOPPEBVCAD Chemotherapy With Optional Limited Radiotherapy in Advanced Hodgkin's Disease Blood, April 15, 1998; 91(8): 2704 - 2712. [Abstract] [Full Text] [PDF]